Evidence map›Paper›PMID 40837099›Full record

ArticleCurrent research in chemical biology2021

Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9.

SeongShick Ryu, Gillian E Gadbois, Andrew J Tao, Benjamin J Fram, Jie Jiang, Bridget Boyle, Katherine A Donovan, Noah M Krupnick, Bethany C Berry, Debabrata Bhunia and 5 more

Abstract read
In one paragraph

Article in Current research in chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

SeongShick RyuKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
Gillian E GadboisDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Andrew J TaoDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Benjamin J FramDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Jie JiangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Bridget BoyleDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Noah M KrupnickDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Bethany C BerryDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Debabrata BhuniaChemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
Injae ShinKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Nathanael S GrayChemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, CA, USA.
Taebo SimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
Fleur M FergusonDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA.

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
Degrading therapeutically important kinases using small moleculesR01CA218278 · NCI · STANFORD UNIVERSITY · PI Eric Sebastian Fischer, NATHANAEL Schiander GRAY · 2019 to 2026
$4.6M
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.R01CA214608 · NCI · DANA-FARBER CANCER INST · PI Eric Sebastian Fischer · 2017 to 2026
$4.0M
Molecular Biophysics Training Grant at UC San DiegoT32GM139795 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Galia Debelouchina, ELIZABETH A. KOMIVES · 2021 to 2026
$3.0M
NCI NIH HHS R01 CA214608NCI NIH HHS R01 CA218278NIDDK NIH HHS U24 DK116204NIGMS NIH HHS T32 GM139795
6 · The paper itself

Abstract

Nek9 is a member of the understudied Nek family of dark kinases. Aberrant activation of Nek9 kinase signaling has been linked to poor keratinocyte differentiation phenotypes, and is a key driver of nevus comedonicus, a rare, localized form of acne. Nek9 also has essential scaffolding roles; during mitosis the non-catalytic C-terminal domain of Nek9 binds to Nek6 and Nek7, releasing them from an auto-inhibitory conformation, and enabling proper mitotic progression. Finally, Nek9 expression has been linked to cancer proliferation. SiRNA mediated Nek9 knock-down in a panel of cancer cell lines induces G1 cell cycle arrest and inhibits proliferation when p53 is also inactivated; cell lines with functional p53 are unaffected. Presently, no selective small molecule Nek9 chemical probes are available, though a subset of promiscuous kinase inhibitors have Nek9 activity. Recently described targeted protein degradation approaches have shown that degrader molecules based on multi-targeted kinase inhibitors may effect selective kinase degradation, despite binding to many targets. In this study we report the identification and SAR of potent degraders of the NEK9 kinase that represent attractive leads for further development. Future work is needed to optimize the selectivity of the compounds.

Indexed as

Never in mitosis A-Related kinase 9Targeted protein degradationUnderstudied kinome

Identifiers

PMID40837099
PMCPMC12364016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.